FDA rejects rare disease drug developed by Cambridge's Akcea

The FDA rejected a drug developed by Cambridge biotech Akcea Therapeutics Inc. in partnership with California-based Ionis Pharmaceuticals that's intended to treat a rare lipid disorder, halting hopes for a treatment for the currently unserved, debilitating disease. Cambridge-based Akcea (Nasdaq: AKCA) and Ionis (Nasdaq: IONS) announced the news about the drug, Waylivra, at the close of trading on Monday. The companies had partnered up to develop the drug using Ionis' antisense technology. Akcea's…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news